Adrián Velázquez-Campoy Selected Research

Inosine Diphosphate (IDP)

10/2021	Design of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function.
11/2019	Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma.
1/2019	Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis.
1/2018	Amphipathic helical peptides hamper protein-protein interactions of the intrinsically disordered chromatin nuclear protein 1 (NUPR1).
1/2017	Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adrián Velázquez-Campoy Research Topics

Disease

8	Neoplasms (Cancer) 10/2021 - 01/2017
5	Infections 12/2019 - 11/2009
4	Adenocarcinoma 11/2019 - 01/2017
1	Metabolic Diseases (Metabolic Disease) 04/2022
1	Phenylketonurias (Phenylketonuria) 04/2022
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2022
1	Pain (Aches) 10/2021
1	Amyloidosis 01/2021
1	Transthyretin-Related Hereditary Amyloidosis 01/2021
1	Cysts 12/2020
1	Pancreatic Cyst 12/2020
1	Protein-Energy Malnutrition (Marasmus) 01/2020
1	Stroke (Strokes) 01/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019
1	Pancreatitis 01/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 11/2017
1	Neoplasm Metastasis (Metastasis) 01/2017
1	Communicable Diseases (Infectious Diseases) 01/2017
1	Meningitis 01/2016
1	Hypercholesterolemia 06/2014
1	Parasitemia 07/2013
1	Malaria 07/2013
1	Mitochondrial Encephalomyopathies (Mitochondrial Encephalomyopathy) 11/2009

Drug/Important Bio-Agent (IBA)

8	Intrinsically Disordered ProteinsIBA 10/2021 - 01/2017
6	Pharmaceutical PreparationsIBA 10/2021 - 07/2013
6	Proteins (Proteins, Gene)FDA Link 10/2021 - 07/2013
5	Inosine Diphosphate (IDP)IBA 10/2021 - 01/2017
3	Biological ProductsIBA 10/2021 - 01/2019
3	NUPR1 inhibitor ZZW-115IBA 01/2020 - 01/2019
2	EnzymesIBA 04/2022 - 01/2017
2	Tyrosine (L-Tyrosine)FDA Link 04/2022 - 11/2017
2	Amyloid (Amyloid Fibrils)IBA 01/2021 - 01/2020
2	FlavodoxinIBA 01/2016 - 11/2009
1	Phenylalanine Hydroxylase (Phenylalanine 4 Monooxygenase)IBA 04/2022
1	Phenylalanine (L-Phenylalanine)FDA Link 04/2022
1	Essential Amino AcidsIBA 04/2022
1	Congenital disorder of glycosylation type 1AIBA 01/2022
1	phosphomannomutaseIBA 01/2022
1	Cyclic PeptidesIBA 10/2021
1	Analgesics (Analgesic Drugs)IBA 10/2021
1	Tolcapone (Tasmar)FDA Link 01/2021
1	Prealbumin (Transthyretin)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 12/2020
1	Thyroid HormonesIBA 01/2020
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2020
1	Nuclear Proteins (Protein, Nuclear)IBA 01/2020
1	FlavinsIBA 01/2020
1	DihydropyridinesIBA 12/2019
1	FlavonoidsIBA 01/2019
1	Antipsychotic Agents (Antipsychotics)IBA 01/2019
1	Trifluoperazine (Stelazine)FDA LinkGeneric 01/2019
1	ChromatinIBA 01/2018
1	Cytochromes c (Cytochrome c)IBA 11/2017
1	Cell Adhesion MoleculesIBA 01/2017
1	IntegrinsIBA 01/2017
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 01/2017
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2017
1	CholesterolIBA 06/2014
1	AntibodiesIBA 07/2013
1	cupredoxinIBA 07/2013
1	rusticyaninIBA 07/2013
1	Peptides (Polypeptides)IBA 01/2011
1	Transfer RNA (tRNA)IBA 11/2009

Therapy/Procedure

1	Therapeutics 01/2021
1	Oral Administration 11/2019